ARMP Key Statistics, Chart & Performance
The current stock price of ARMP is 6.4 USD. In the past month the price increased by 13.07%. In the past year, price increased by 210.68%.
ARMP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARMP. When comparing the yearly performance of all stocks, ARMP is one of the better performing stocks in the market, outperforming 98.38% of all stocks.
ARMP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ARMP. ARMP has a bad profitability rating. Also its financial health evaluation is rather negative.
ARMP Financial Highlights
Over the last trailing twelve months ARMP reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS decreased by -15.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARMP Forecast & Estimates
7 analysts have analysed ARMP and the average price target is 12.24 USD. This implies a price increase of 91.25% is expected in the next year compared to the current price of 6.4.
For the next year, analysts expect an EPS growth of -202.08% and a revenue growth -3.64% for ARMP
ARMP Ownership
ARMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About ARMP
Company Profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Company Info
ARMATA PHARMACEUTICALS INC
5005 Mcconnell Ave
Los Angeles CALIFORNIA 90292 US
CEO: Todd R. Patrick
Employees: 60
Phone: 13106652928
ARMATA PHARMACEUTICALS INC / ARMP FAQ
What does ARMATA PHARMACEUTICALS INC do?
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
What is the current price of ARMP stock?
The current stock price of ARMP is 6.4 USD. The price increased by 0.31% in the last trading session.
Does ARMATA PHARMACEUTICALS INC pay dividends?
ARMP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARMP stock?
ARMP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ARMP stock?
ARMP stock is listed on the NYSE Arca exchange.
What is the Price/Earnings (PE) ratio of ARMATA PHARMACEUTICALS INC (ARMP)?
ARMATA PHARMACEUTICALS INC (ARMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.32).